MGMT and glioblastoma: In patients with newly diagnosed GBM, the addition of TTFields therapy to maintenance TMZ resulted in a median OS of 20.9 months compared with 16.0 months for TMZ alone, with survival improved regardless of age, extent of resection, or MGMT methylation status [1].